XBI strategy verdict
SPDR S&P Biotech (XBI) strategy verdict: The strategy underperforms buy-and-hold on XBI in its observed regime. Across all tickers, the pullback and risky-accumulation strategies beat holding in 89.8% of crash-regime backtests; that edge may not apply here.
Closed trades: 140 of 185 (75.7%) made money in default-settings backtests of the pullback strategy. A win rate counts closed trades only; a position that is still open and down is not in it.
Against buy-and-hold: 12.3% of 553 backtests beat holding XBI over the same dates (68 of 553). The median backtest's gap to holding was -10.1 points a year.
Median return across its backtests: 1.6% a year for the strategy, against 11.5% a year for buying and holding XBI over the same dates.
Average Sharpe ratio 0.25; average maximum drawdown -35.5%.
Risk level: informed gamble. Dominant regime: modest. History tested: about 21 years.
Backtests are research, not advice. Past results do not predict future returns, and most strategies we test do not beat holding.
What is XBI?
State Street SPDR S&P Biotech ETF (XBI) is a sector fund that follows the S&P Biotechnology Select Industry Index of US biotech companies. The index is modified equal weighted, so no single large company dominates the fund.
Also searched for as: xbi etf, biotech etf, spdr s&p biotech etf, s&p biotech etf, equal weight biotech etf.